AI주식인사이트AI Stock Insight
B

바이오에프디엔씨

251120KOSDAQ기초 의약물질 제조업

59.5 / 100

Reference Date: 2026-04-13

Financial Score30.0 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioFDC specializes in developing and manufacturing effective substances for cosmetics, health foods, and pharmaceuticals using plant cell platform technology, leveraging gene editing and high-frequency processing techniques for a unique cultivation platform. Key products include plant cell extracts and growth factor-based cosmetic ingredients, with plans to commercialize pharmaceuticals in the medium to long term.

Number of Employees

78people

Average Salary

55.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
17.77Industry Average 33.456.5Point

Lower than industry avg (good)

PBR
1.73Industry Average 2.034.0Point

In line with industry avg

ROE
10.03Industry Average -4.293.5Point

Well below industry avg

Debt Ratio
0.35Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲11.2% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲12.6% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 9.1% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (10%, downtrend)

Current 13,900Won52-week high 22,25052-week low 12,910
1-month return3.0Point

1m -0.71% (flat)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-08
  • Neutral정기주주총회결과2026-03-30
  • Neutral감사보고서제출2026-03-20
  • Neutral사업보고서 (2025.12)2026-03-20